Ardelyx is developing RDX002 a novel, minimally-systemic phosphate transport inhibitor for the treatment of phosphorus disorders in Chronic Kidney Disease (CKD) and end-stage renal disease (ESRD). This molecule is a first-in-class drug candidate for intestinal phosphate blockade.
RDX002 is a potent, minimally-systemic NaP2b inhibitor discovered after extensive medicinal chemistry efforts and in vitro/in vivo screening. RDX002 reduces phosphate absorption in the gut and demonstrates results that are, at a minimum, comparable to commercial phosphate binders at a much lower dose. Ardelyx has generated data that demonstrates an additive effect of RDX002 when combined with currently available phosphate binders.
RDX002 has the potential to treat secondary hyperparathyroidism and reduce morbidity and mortality risk in the CKD population, representing 20 million people in the US alone.
